Literature DB >> 25380625

Circulating levels of apelin, glucagon-like peptide and visfatin in hypercholesterolemic-hyperhomocysteinemic guinea-pigs: their relation with NO metabolism.

Zeynep Kusku-Kiraz1, Sema Genc, Seldag Bekpinar, Yesim Unlucerci, Vakur Olgac, Mujdat Uysal, Figen Gurdol.   

Abstract

The aim of this study was to determine the levels of regulatory peptides apelin, glucagon-like peptide (GLP-1) and visfatin in hypercholesterolemic and hyperhomocysteinemic state and to examine their relation with nitric oxide (NO) metabolism. 32 Male guinea pigs were divided into four groups and each group was fed as follows: (a) commercial chow, (b) cholesterol (chol)-rich diet, (c) methionine (meth)-rich diet, and (d) chol + meth-rich diet. Blood samples were drawn at the end of 10 weeks, and abdominal aorta was dissected for histopathological examination. Serum insulin, GLP-1, apelin, visfatin, and nitrotyrosine concentrations were measured by the manufacturer's kits based on ELISA; asymmetric dimethylarginine (ADMA) and arginine levels were measured by the high performance liquid chromatography. Homocysteine level was measured by the chemiluminescence immunoassay; glucose, total chol and triglyceride levels were measured by the autoanalyzer. The microscopic examination of aorta indicated varying degrees of vascular disturbance in chol- and chol + meth-fed groups. High levels of chol and homocysteine, accompanied with significantly low levels of apelin and GLP-1 were detected in the plasma. Visfatin, ADMA, and nitrotyrosine levels both in chol- and chol + meth-fed groups were significantly higher than those in control animals, whereas arginine and arginine/ADMA ratio were lower. This study indicated that circulating levels of apelin, GLP-1, and visfatin are markedly altered during the development of atherosclerotic changes in close association with chol, homocysteine, NO, and ADMA levels. The measurements of these peptides in serum may help for the diagnosis and follow-up of vascular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25380625     DOI: 10.1007/s11010-014-2263-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  46 in total

1.  The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.

Authors:  Aya Shiraki; Jun-ichi Oyama; Hiroshi Komoda; Machiko Asaka; Aiko Komatsu; Masashi Sakuma; Kazuhisa Kodama; Yoshiko Sakamoto; Norihiko Kotooka; Tetsuaki Hirase; Koichi Node
Journal:  Atherosclerosis       Date:  2012-01-04       Impact factor: 5.162

2.  Dietary methionine level affects linoleic acid metabolism through phosphatidylethanolamine N-methylation in rats.

Authors:  K Sugiyama; A Kumazawa; H Zhou; S Saeki
Journal:  Lipids       Date:  1998-03       Impact factor: 1.880

Review 3.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

4.  Apelin: a new plasma marker of cardiopulmonary disease.

Authors:  Jens Peter Goetze; Jens F Rehfeld; Jørn Carlsen; Regitze Videbaek; Claus B Andersen; Soeren Boesgaard; Lennart Friis-Hansen
Journal:  Regul Pept       Date:  2005-11-02

5.  Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.

Authors:  Miao-Pei Chen; Fu-Mei Chung; Dao-Ming Chang; Jack C-R Tsai; Han-Fen Huang; Shyi-Jang Shin; Yau-Jiunn Lee
Journal:  J Clin Endocrinol Metab       Date:  2005-10-18       Impact factor: 5.958

Review 6.  Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk.

Authors:  Rainer H Böger; Renke Maas; Friedrich Schulze; Edzard Schwedhelm
Journal:  Pharmacol Res       Date:  2009-07-22       Impact factor: 7.658

7.  Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.

Authors:  K Tatemoto; M Hosoya; Y Habata; R Fujii; T Kakegawa; M X Zou; Y Kawamata; S Fukusumi; S Hinuma; C Kitada; T Kurokawa; H Onda; M Fujino
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

8.  Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus.

Authors:  Sema Uslu; Nur Kebapçi; Mehmet Kara; Cengiz Bal
Journal:  Exp Ther Med       Date:  2012-04-23       Impact factor: 2.447

9.  Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine.

Authors:  Markus C Stühlinger; Roberta K Oka; Eric E Graf; Isabella Schmölzer; Barbara M Upson; Om Kapoor; Andrzej Szuba; M Rene Malinow; Thomas C Wascher; Otmar Pachinger; John P Cooke
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

10.  Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans.

Authors:  Katja Piotrowski; Melanie Becker; Julia Zugwurst; Ingeborg Biller-Friedmann; Gerald Spoettl; Martin Greif; Alexander W Leber; Alexander Becker; Rüdiger P Laubender; Corinna Lebherz; Burkhard Goeke; Nikolaus Marx; Klaus G Parhofer; Michael Lehrke
Journal:  Cardiovasc Diabetol       Date:  2013-08-16       Impact factor: 9.951

View more
  3 in total

1.  MCD diet-induced steatohepatitis is associated with alterations in asymmetric dimethylarginine (ADMA) and its transporters.

Authors:  Laura G Di Pasqua; Clarissa Berardo; Vittoria Rizzo; Plinio Richelmi; Anna Cleta Croce; Mariapia Vairetti; Andrea Ferrigno
Journal:  Mol Cell Biochem       Date:  2016-06-29       Impact factor: 3.396

Review 2.  Mechanisms of obesity-induced metabolic and vascular dysfunctions.

Authors:  Reem T Atawia; Katharine L Bunch; Haroldo A Toque; Ruth B Caldwell; Robert W Caldwell
Journal:  Front Biosci (Landmark Ed)       Date:  2019-03-01

Review 3.  Adipocytokines: Are they the Theory of Everything?

Authors:  Pierre S Maximus; Zeina Al Achkar; Pousette F Hamid; Syeda S Hasnain; Cesar A Peralta
Journal:  Cytokine       Date:  2020-06-16       Impact factor: 3.861

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.